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Introduction and purpose
Molecular imaging and nanomedicine approaches to the
diagnosis, monitoring and treatment of cardiovascular
diseases, e.g. atherosclerosis, could have significant conse-
quence on medical practice and outcomes. Due to the
exquisite sensitivity of MR to magnetic field disturbances
of iron oxides (IO), a variety of IO-based agents have been
utilized. However, despite many elegant new imaging
techniques, the highly-sensitive detection and visualiza-
tion of IO still depends on the disruption of the local mag-
netic field. Contrary to typical IO agents, we have
presented a novel colloidal iron oxide nanoparticle
(CION) that encapsulates multiple magnetite nanocrys-
tals suspended in oil, encased in a lipid membrane
thereby reducing T2* effects such that T1 effects can be
detected. The purpose of this work was to develop a CION
with improved longitudinal relaxivity (r1) and the ability
to carry drugs.
Methods
To evaluate the role of IO concentration within the oil
core, CION were created with [IO] of 7.5%, 15% and 45%
(w/v) Fe3O4, both with and without cross-linking the
outer lipid membrane. To compare the effect of iron
phase, CION was made with mixed-phase maghemite
(Fe2O3-Fe3O4) at 7.5% (w/v). CION were characterized
using dynamic light scattering, vibrating sample magne-
tometer, atomic force microscopy (AFM) and transmis-
sion electron microscopy (TEM). The r1 was calculated at
1.5 T using the Look-Locker technique to measure T1 of
serial dilutions of CION. To demonstrate drug-carrying
capability, fumagillin was incorporated into the outer sur-
factant. A dissolution study was performed over 3 d.
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T1w images of various CION formulationsFigure 1
T1w images of various CION formulations. Cross-link-
ing (top row) the outer lipid membrane dearly increases the 
T1 effects compared to without cross-linking (bottom row) 
as soes reducing the overall IO concentraion within the oily 
core of the CION (columns). At the highest iron concentra-
tion within the CION (45% w/v), the T2* effects overwhelm 
the T1 effects (bottom right).Page 1 of 2
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Hydrodynamic diameter and zeta potential of the CIONs
ranged from 110-300 nm and 23 to 40 mV, respectively,
depending on composition. AFM revealed an asymmetric
(deformable) particle size of 114 ± 22 nm (height) by 228
± 69 nm (diameter). TEM confirmed that the iron nanoc-
rystals were retained in the oil core. In all cases, r1
([Fe]mMs-1) of the cross-linked CION was 2-3× greater
than the non-cross-linked version. Decreasing magnetite
loading (45%, 15%, 7.5%) increased r1 from 1.8, 4.5, to
7.7, respectively. Comparing CION comprising magnetite
vs. mixed-phased maghemite nanocrystals gave an r1 of
7.7 vs. 1.3, respectively, the lower susceptibility pure
phase performing better. T1-weighted imaging confirmed
r1 relationships (see Figure 1). For loading fumagillin into
CION, 98% efficiency was achieved with less than 1%
released over 3 d.
Conclusion
Targeted CION is a positive-contrast T1 agent wherein
pure magnetite, low Fe concentration, and cross-linking
each augment overall r1 relaxivity. Additionally, CION
offers a good potential platform for targeted drug delivery
exhibiting excellent drug retention in dissolution.Page 2 of 2
(page number not for citation purposes)
